Home Newsfeeds Truist Securities Downgrades PacWest Banc to Hold, Announces $26 Price Target

Truist Securities Downgrades PacWest Banc to Hold, Announces $26 Price Target

Truist Securities analyst Brandon King downgrades PacWest Banc (NASDAQ:PACW) from Buy to Hold and announces $26 price target.

byBenzinga Newsdesk

December 9, 2022

1 minute read

Truist Securities analyst Brandon King downgrades PacWest Banc (NASDAQ:PACW) from Buy to Hold and announces $26 price target.

BREAKING: Elon Musk Sells Nearly $4B In Tesla Shares In 3 Days

By Benzinga Overnight Desk

November 8, 9:48 PM

Tesla Inc. (NASDAQ: TSLA) CEO Elon Musk sold 19.5 million shares, estimated to be worth nearly $4 billion, in the electric vehicle maker between Nov. 4 and Nov. 8, filings made with the U.S. Securities and Exchange Commission show.

TSLA

Weekly Jobless Claims Rise Slightly More Than Expected: What You Need To Know

By Piero Cingari

May 4, 8:54 AM

The number of Americans registering for unemployment benefits rose by 13,000 to 242,000 in the week ending April 29, the U.S. Labor Department reported Thursday. The outcome was slightly above market estimates of 240,000.

SPY

Check Out 3 Real Estate Stocks With Over 6% Dividend Yields From Wall Street’s Most Accurate Analysts

By Lisa Levin

August 1, 8:31 AM

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

BNL

‘Provention Bio’s Recently Approved Drug Tzield (Teplizumab) For The Delay Of Clinical Type 1 Diabetes Has Been Added To The Department Of Veterans Affairs National Acquisition Center Drug Catalog’

By Benzinga Newsdesk

January 17, 12:52 PM

https://www.vendorportal.ecms.va.gov/NAC/Pharma/Details?NDC=73650031601&CNT=36F79723D017E

PRVB

Truist Securities Downgrades PacWest Banc to Hold, Announces $26 Price Target

Related Posts

BREAKING: Elon Musk Sells Nearly $4B In Tesla Shares In 3 Days

Weekly Jobless Claims Rise Slightly More Than Expected: What You Need To Know

Check Out 3 Real Estate Stocks With Over 6% Dividend Yields From Wall Street’s Most Accurate Analysts

‘Provention Bio’s Recently Approved Drug Tzield (Teplizumab) For The Delay Of Clinical Type 1 Diabetes Has Been Added To The Department Of Veterans Affairs National Acquisition Center Drug Catalog’